|
Delayed
Sao Paulo
01:06:00 21/10/26 am AEDT
|
5-day change | 1st Jan Change | ||
| 64.98 BRL | +0.25% |
|
+4.44% | +13.34% |
| 19/10 | Gilead Sciences, Inc. Presents New Findings From Its HIV And Antiviral Research And Development Programs At IDWeek 2026 | CI |
| 19/10 | Gilead's pill succeeds in mid-stage bowel disease trial | RE |
| Market Cap | 190B 960B 169B 157B 142B 267B 17,995B 272B 1,880B 739B 9,405B 712B 697B 30,066B | P/E 2026 * |
-44.7x | P/E 2027 * | 19x |
|---|---|---|---|---|---|
| Enterprise Value | 211B 1,067B 188B 174B 158B 297B 20,012B 302B 2,090B 822B 10,459B 792B 775B 33,435B | EV / Sales 2026 * |
6.87x | EV / Sales 2027 * | 6.19x |
| Free-Float |
99.89% | Yield 2026 * |
2.15% | Yield 2027 * | 2.19% |
Last Transcript: Gilead Sciences, Inc.
| 1 day | +0.25% | ||
| 1 week | +4.44% | ||
| Current month | -1.46% | ||
| 1 month | +1.04% | ||
| 3 months | +14.71% | ||
| 6 months | +22.26% | ||
| Current year | +13.34% |
| 1 week | 63.84 |  | 67.38 |
| 1 month | 59.28 | | 67.38 |
| Current year | 52.08 | | 67.38 |
| 1 year | 52.08 | | 67.38 |
| 3 years | 27.26 | | 67.38 |
| 5 years | 22.04 | | 67.38 |
| 10 years | 17.05 | | 67.38 |
| Manager | Title | Age | Since |
|---|---|---|---|
Daniel O'Day
CEO | Chief Executive Officer | 61 | 01/03/2019 |
Andrew Dickinson
DFI | Director of Finance/CFO | 56 | 01/11/2019 |
Keeley Wettan
CMP | Compliance Officer | - | 18/12/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Kelly Kramer
BRD | Director/Board Member | 58 | 19/08/2016 |
| Director/Board Member | 73 | 01/01/2018 | |
Harish Manwani
BRD | Director/Board Member | 72 | 09/05/2018 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.25% | +4.44% | - | - | 190B | |
| +4.72% | +11.55% | +60.85% | +122.57% | 1,106B | |
| +2.30% | +4.22% | +33.75% | +69.35% | 612B | |
| +2.18% | +4.88% | +23.99% | +96.77% | 500B | |
| +2.39% | +8.17% | +38.46% | +62.85% | 367B | |
| +3.15% | +4.28% | +71.52% | +44.20% | 354B | |
| +1.66% | +5.45% | +20.80% | +48.35% | 286B | |
| +1.57% | +5.36% | -0.24% | +20.17% | 256B | |
| +2.34% | +5.32% | +43.34% | +55.94% | 230B | |
| +1.85% | +4.93% | +26.07% | +99.50% | 190B | |
| Average | +2.08% | +6.02% | +35.39% | +68.86% | 433.35B | |
| Weighted average by Cap. | +2.69% | +7.02% | +41.07% | +80.96% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 30.73B 155B 27.39B 25.37B 23.07B 43.29B 2,913B 44.01B 304B 120B 1,523B 115B 113B 4,868B | 32.84B 166B 29.27B 27.11B 24.65B 46.26B 3,113B 47.02B 325B 128B 1,627B 123B 121B 5,202B |
| Net income | -4.26B -21.52B -3.79B -3.51B -3.2B -6B -404B -6.1B -42.16B -16.58B -211B -15.97B -15.64B -674B | 10.27B 51.91B 9.15B 8.48B 7.71B 14.47B 974B 14.7B 102B 39.99B 509B 38.53B 37.72B 1,627B |
| Net Debt | 21.27B 108B 18.96B 17.57B 15.97B 29.97B 2,017B 30.46B 211B 82.85B 1,054B 79.81B 78.14B 3,370B | 13.62B 68.86B 12.14B 11.25B 10.23B 19.19B 1,291B 19.5B 135B 53.04B 675B 51.1B 50.03B 2,157B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 21/10/26 | BRL 64.98 | +0.25% | 1 |
| 19/10/26 | BRL 64.82 | -1.50% | 2 |
| 16/10/26 | BRL 65.81 | -1.98% | 1,782 |
| 15/10/26 | BRL 67.14 | +4.22% | 5 |
| 14/10/26 | BRL 64.42 | +3.54% | 221 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GILD Stock
- GILD34 Stock
Select your edition
All financial news and data tailored to specific country editions
